For Health Care Professionals Outside the US
  • For the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
  • For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib
  • For the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
  • For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib
They Have Plans. You Have ZYKADIA.

Please see the Summary of Product Characteristics and Basic Succinct Statement available on this website.

Overall safety profile was similar between doses except for improvement in GI tolerability.
Dose optimization study

DOSE OPTIMIZATION STUDY (450-mg DOSE WITH FOOD)

450-mg recommended dose with food improves GI tolerability while providing similar exposure and comparable efficacy and safety to the 750-MG fasted dose1,2
First-line efficacy
First-line
Efficacy*
In patients with and
without brain metastases3
Second-line efficacy
Second-line
Efficacy*
Significantly extended PFS in previously treated patients vs chemotherapy3
GI, gastrointestinal; PFS, progression-free survival.
Data based on 750-MG fasted dose.
References: 1. Data on file. Novartis Pharmaceuticals Corp; 2018. 2. Cho BC, Kim D-W, Bearz A, et al. ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol.
2017;12(9):1357-1367. 3. Zykadia Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2017.